NEWARK, Del.--(BUSINESS WIRE)--June 14, 2006--Strategic Diagnostics Inc. (Nasdaq:SDIX - News) - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today announced that it has received an initial order for Genomic Antibodies(TM) from a top ten pharmaceutical company. Scientists from this company require Genomic Antibodies(TM) to classes of proteins for which conventional antibody generation is typically unsuccessful. These scientists have unsuccessfully attempted to make antibodies to some of the protein targets in this initial order, demonstrating the importance of these difficult targets in drug discovery and development and highlighting the potential for Genomic Antibodies(TM) to support their research.
